Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chen, Xiao Long ^a   Chen, Xin Zu ^a   Yang, Chen ^a   Liao, Yan Biao ^a   Li, He ^a   Wang, Li ^a   Yang, Kun ^a   Li, Ka ^a   Hu, Jian Kun ^a   Zhang, Bo ^a   Chen, Zhi Xin ^a   Chen, Jia Ping ^a   Zhou, Zong Guang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; OXALIPLATIN;

ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DIARRHEA; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; INFECTION; LEUKOPENIA; META ANALYSIS; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STOMACH CARCINOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TIME TO PROGRESSION; TOXIC HEPATITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DISEASE PROGRESSION; FLUOROURACIL; HUMANS; PALLIATIVE CARE; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84875944508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060320     Document Type: Article

References (62)

1. Wagner AD, Wedding U, (2009) Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging 26: 627-646.
2. Bittoni A, Maccaroni E, Scartozzi M, Berardi R, Cascinu S, (2010) Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci 14: 309-314.
3. Catalano V, Labianca R, Beretta GD, Gatta G, De Braud F, et al. (2009) Gastric cancer. Crit Rev Oncol Hematol 71: 127-164.
4. Ajani JA, (1998) Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park) 12(10 (Suppl 7): 44-47.
5. Tsai JY, Safran H, (2003) Status of treatment for advanced gastric carcinoma. Curr Oncol Rep 5: 210-218.
6. Van Cutsem E, Van de Velde C, Roth A, Lordick F, Kohne CH, et al. (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organization for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44: 182-194.
7. Hu JK, Yang K, Zhang B, Chen XZ, Chen ZX, et al. (2009) D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery. Surg Today 39: 207-213.
8. Yang K, Chen XZ, Hu JK, Chen ZX, Chen JP, (2009) Effectiveness and safety of splenectomy for gastric carcinoma: a meta-analysis. World J Gastroenterol 15: 5352-5359.
9. Chen XZ, Hu JK, Zhou ZG, Rui YY, Yang K, et al. (2010) Meta-analysis of effectiveness and safety of D2 plus para-aortic lymphadenectomy for resectable gastric cancer. J Am Coll Surg 210: 100-105.
10. Hu JK, Li CM, Chen XZ, Chen ZX, Zhou ZG, et al. (2007) The effectiveness of intravenous 5-Flurouracil-containing chemotherapy after curative resection for gastric carcinoma: a systematic review of published randomized controlled trials. J Chemotherapy 19: 359-374.
11. Hu JK, Chen ZX, Zhou ZG, Zhang B, Tian J, et al. (2002) Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol 8: 1023-1028.
12. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, et al. (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11: 301-306.
13. Das P, Ajani JA, (2005) Gastric and gastro-oesophageal cancer therapy. Expert Opin Pharmacother 6: 2805-2812.
14. Chen XZ, Yang K, Liu J, Chen XL, Hu JK, (2011) Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer. World J Gastroenterol 17: 4542-4544.
15. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, et al. (2011) Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 29: 868-874.
16. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, et al. (2010) Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 28: 2947-2951.
17. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, et al. (2010) Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66: 721-728.
18. Takayama T, Sato Y, Sagawa T, Okamoto T, Nagashima H, et al. (2007) Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 97: 851-856.
19. Ohtsu A, (2005) Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8: 95-102.
20. Van Cutsem E (2004) Docetaxel in gastric cancer. Eur J Cancer (Suppl 7): 52-58.
21. Cortes JE, Pazdur R, (1994) Docetaxel. J Clin Oncol 13: 2643-2655.
22. Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, et al. (2002) Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32: 248-254.
23. Haller DG, Misset JL, (2002) Docetaxel in advanced gastric cancer. Anticancer Drugs 13: 451-460.
24. Giuliani F, Gebbia V, De Vita F, Maiello E, Di BM, et al. (2003) Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 23: 4219-4222.
25. Chen XZ, Jiang K, Hu JK, Zhang B, Gou HF, et al. (2008) Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol 14: 2715-2722.
26. Roth AD, Ajani JA (2003) Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol (Suppl 2): 41-44.
27. Yamamoto K, Fujiwara Y, Nishida T, Takiguchi S, Nakajima K, et al. (2009) Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer Res 29: 4211-4215.
28. Ajani JA, (2002) Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park) 16(6 (Suppl 6): 89-96.
29. Oh DY, Kim TY, Kwon JH, Lee JJ, Joh Y, et al. (2005) Docetaxel +5-fluorouracil+cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J Clin Oncol 35: 380-385.
30. Oh SC, Park KH, Choi IK, Yoon SY, Kim SJ, et al. (2005) Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer. Br J Cancer 92: 827-831.
31. Park SR, Chun JH, Kim YW, Lee JH, Choi IJ, et al. (2005) Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol 28: 433-438.
32. Lorenzen S, Hentrich M, Haberl C, Lorenzen S, Hentrich M, et al. (2007) Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18: 1673-1679.
33. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, et al. (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25: 3205-3209.
34. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, et al. (2007) Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25: 3210-3216.
35. Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z, (2006) Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 6: 274-279.
36. Li CP, Chen JS, Chen LT, Yen CJ, Lee KD, et al. (2010) A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Br J Cancer 103: 1343-1348.
37. Van Cutsem E (2004) The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist (Suppl 2): 9-15.
38. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, et al. (2007) Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25: 3217-3223.
39. Jadad AR, Moore RA, Carroll D, (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
40. Miller AB, Hoogstraten B, Staquet M, Winkler A, (1981) Reporting Results of cancer treatment. Cancer 47: 207-214.
41. Higgins JPT, Green S (2008) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration. Available: http://www.cochrane-handbook.org. Accessed 2013 Mar 13.
42. Chu JH, Zhang Y, Liu DF, Ji HM (2006) Weekly docetaxel combined with cisplatin of fluorouracil for advanced gastric carcinoma. Chin J Clin Oncol 11: 541-542. [Chinese].
43. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997.
44. Li XQ, Gu HG, Guo JW, Zhu XX (2007) Clinical study of continuous venous infusion of low-dose 5-Fu and cisplatin combined with weekly docetaxel for treatment of advanced gastric cancer. Modern Oncol 15: 659-661. [Chinese].
45. Wu GC, Bian XS, Wei CH, Song ZX (2008) A comparison of TCF and FLP for late stage of gastric carcinoma. J Shandong Med 48: 73-74. [Chinese].
46. Zhang FL, Hu YF, Duan W (2008) Clinical observation of docetaxel combined with LFP for late stage gastric carcinoma. Chin J Clin Oncol 35: 1397-1398, 1406. [Chinese].
47. Hou AJ, Hu Y, Zhou W, Zhang HW, Huang YL, et al. (2009) Weekly docetaxel, cisplatin and low dose of fluorouracil for advanced gastric carcinoma: a randomized clinical trial. Tumor 29: 160-163. [Chinese].
48. Zhao F, Wang Q, Zhang JW, Hang M, Chen SB (2009) Therapeutic evaluation of docetaxel-combined chemotherapy for advanced gastric carcinoma. Acta Universitatis Medicinalis NanJing (Natural Science) 29: 237-239. [Chinese].
49. Shen YC, Chu JH (2009) Observation of weekly dose of docetaxel combined with small doses of cisplatin, 5-fluorouracil continuous intravenous infusion treatment of advanced gastric cancer. J Basic Clin Oncol 22: 318-320. [Chinese].
50. Liang B, Han N, Yang JM (2010) Clinical study of comparative efficacy of DCF regimen vs. ECF regimen in treating advanced gastric cancer. Chin J Clin Oncol Rehabil 17: 59-61. [Chinese].
51. Gao H, Ding X, Wei D, Xu T, Cheng P, et al. (2010) Docetaxel versus epirubic in combined with cisplatin, leucovorin and fluorouracil for advanced gastric carcinoma as first line therapy: a randomized clinical trial. Chin J Clin Oncol 15: 529-533. [Chinese].
52. Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, et al. (2000) Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 23: 341-344.
53. Makatsoris T, Papakostas P, Kalofonos HP, Xanthakis I, Tsavdaridis D, et al. (2007) Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. Med Oncol 24: 301-307.
54. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, et al. (2010) Gastric cancer. J Natl Compr Canc Netw 8: 378-409.
55. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, et al. (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 3: CD004064.
56. Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, et al. (2004) Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24: 1843-1851.
57. Rino Y, Takanashi Y, Yukawa N, Saeki H, Wada H, et al. (2006) A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. Anticancer Res 26: 1455-1462.
58. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, et al. (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94: 1803-1808.
59. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, et al. (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407.
60. Kakeji Y, Oki E, Egashira A, Sadanaga N, Takahashi I, et al. (2009) Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Oncology 77: 49-52.
61. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, et al. (2010) Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66: 721-728.
62. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6: e1000097 doi:10.1371/journal.pmed1000097.